CASI Pharmaceuticals, Inc, a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone240-864-2600
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees124
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions
What is CASI Pharmaceuticals' stock symbol?
CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."
How were CASI Pharmaceuticals' earnings last quarter?
CASI Pharmaceuticals Inc (NASDAQ:CASI) released its quarterly earnings data on Friday, August, 9th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. View CASI Pharmaceuticals' Earnings History.
When is CASI Pharmaceuticals' next earnings date?
What price target have analysts set for CASI?
1 Wall Street analysts have issued 1 year price targets for CASI Pharmaceuticals' stock. Their predictions range from $7.00 to $7.00. On average, they expect CASI Pharmaceuticals' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 109.0% from the stock's current price. View Analyst Price Targets for CASI Pharmaceuticals.
What is the consensus analysts' recommendation for CASI Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CASI Pharmaceuticals.
Has CASI Pharmaceuticals been receiving favorable news coverage?
News coverage about CASI stock has trended somewhat negative on Monday, InfoTrie reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. CASI Pharmaceuticals earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for CASI Pharmaceuticals.
Who are some of CASI Pharmaceuticals' key competitors?
Some companies that are related to CASI Pharmaceuticals include Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), Twist Bioscience (TWST), BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), NanoString Technologies (NSTG), Vericel (VCEL), AVITA MED LTD/S (AVMXY), Mesoblast (MESO), GENFIT S A/ADR (GNFT), Voyager Therapeutics (VYGR) and Osiris Therapeutics (OSIR).
What other stocks do shareholders of CASI Pharmaceuticals own?
Who are CASI Pharmaceuticals' key executives?
CASI Pharmaceuticals' management team includes the folowing people:
- Dr. Wei-Wu He, Chairman & CEO (Age 54)
- Mr. George Chi C.F.A., CPA, Chief Financial Officer (Age 50)
- Dr. Wei Zhang Ph.D., Pres of CASI (Beijing) Pharmaceuticals Co., Ltd (Age 60)
- Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 49)
- Ms. Sara B. Capitelli, VP of Fin. & Principal Accounting Officer (Age 53)
Who are CASI Pharmaceuticals' major shareholders?
CASI Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.25%), Wellington Shields Capital Management LLC (1.19%), Northern Trust Corp (0.63%), Charles Schwab Investment Management Inc. (0.33%), Wells Fargo & Company MN (0.08%) and AQR Capital Management LLC (0.04%). Company insiders that own CASI Pharmaceuticals stock include Brian D Coleman, China Growth Fund Idg-Accel II, Spectrum Pharmaceuticals Inc and Wei-Wu He. View Institutional Ownership Trends for CASI Pharmaceuticals.
Which institutional investors are selling CASI Pharmaceuticals stock?
Which institutional investors are buying CASI Pharmaceuticals stock?
CASI stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Charles Schwab Investment Management Inc., Susquehanna International Group LLP, Jane Street Group LLC, Wells Fargo & Company MN and Northern Trust Corp. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Brian D Coleman, China Growth Fund Idg-Accel II, Spectrum Pharmaceuticals Inc and Wei-Wu He. View Insider Buying and Selling for CASI Pharmaceuticals.
How do I buy shares of CASI Pharmaceuticals?
Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is CASI Pharmaceuticals' stock price today?
One share of CASI stock can currently be purchased for approximately $3.35.
How big of a company is CASI Pharmaceuticals?
CASI Pharmaceuticals has a market capitalization of $320.66 million. The biotechnology company earns $-27,470,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe.View Additional Information About CASI Pharmaceuticals.
What is CASI Pharmaceuticals' official website?
How can I contact CASI Pharmaceuticals?
CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]
MarketBeat Community Rating for CASI Pharmaceuticals (NASDAQ CASI)
MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote "Outperform" if you believe CASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
